<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04076683</url>
  </required_header>
  <id_info>
    <org_study_id>2016-A01411-50</org_study_id>
    <nct_id>NCT04076683</nct_id>
  </id_info>
  <brief_title>Algorithm for Apherisis Monitoring and Prescription Assistance in Sickle Cell Patients (ALGODREP)</brief_title>
  <acronym>ALGODREP</acronym>
  <official_title>Validation d'Une Stratégie de Programme Transfusionnel Par Erythraphérèse basée Sur un Algorithme d'Aide à la Prescription Transfusionnelle Chez Les Patients Adultes Drépanocytaires</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Etablissement Français du Sang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Université Paris Est Créteil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Etablissement Français du Sang</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to prove the superiority of a procedure which calculates
      the volume of RBCs to transfuse and the time between apheresis based on this algorithm,
      compared to the current procedure. The primary endpoint would be the number of patients with
      individually achieved objectives in terms of % HbS before each apheresis (which reflects the
      effectiveness of the previous apheresis) over a period of 12 months. The secondary objectives
      would be to compare the volume differences of transfused RBCs in both groups over a period of
      12 months, the occurrence of clinical events and the satisfaction of patients and physicians.

      The investigators hope that this study would improve the efficiency and the performance of
      apheresis in sickle cell patients. The investigators also hope to facilitate the organization
      of procedures with the flexibility that would allow the use of this algorithm.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sickle cell disease (SCD) is the most common genetic disease leading to abnormal hemoglobin
      (HbS). Chronic complications can be severe and affect multiple organs. Among them,
      cerebrovascular disease is one of the most serious leading to a high risk of stroke. These
      complications often require blood exchange transfusions (BET) in order to replace red blood
      cells (RBC) containing HbS (from patients) by GR containing HbA (blood donors), and thereby
      stop the harmful pathophysiological cascade. The indications of long-term apheresis are
      mostly, but not exclusively, represented by cerebral vasculopathy (85% in our center), and
      chronic organ damages. Long-term BET in cerebral vasculopathy may considerably reduce the
      risk of stroke while stopping them leads to a recurrence of this risk, hence there is a need
      to do them regularly (on average every 4 to 6 weeks) with an objective of HbS ≤ 30%. This
      objective may be less stringent in the case of other indications.

      Two methods are used: a manual method which is feasible anywhere and the apheresis which is
      preferred because of its better efficacy in achieving the targets of HbS percentage. It also
      limits transfusion hemochromatosis.

      The volume required for BET by apheresis as well as the optimal period between apheresis
      sessions are empirically determined.

      In our practice, the investigators noticed that this method did not allow to steadily
      obtaining the %HbS objective and the interval between apheresis was variable, in part
      conditioned by the availability of machines. This implies a real risk of occurrence of
      recurrent stroke in patients with cerebral vascular disease and may cause a lack of
      flexibility in the timing of appointments.

      Thereby the principal investigator and the biostatistician created an algorithm to compute
      the volume of blood to be transfused and the interval between apheresis which are necessary
      to maintain an individual objective of HbS percentage. This algorithm has been obtained by
      statistical analysis of apheresis performed at Henri Mondor Hospital over a period of 3
      years.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2019</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with individually achieved objectives in terms of % HbS</measure>
    <time_frame>For each apherisis over a 12 months period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Volume of transfused RBCs</measure>
    <time_frame>For each apherisis over a 12 months period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of transfused RBCs</measure>
    <time_frame>For each apherisis over a 12 months period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of apherisis per participant</measure>
    <time_frame>Over a 12 months period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematocrit (percentage)</measure>
    <time_frame>For each apherisis over a 12 months period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin (g/dL)</measure>
    <time_frame>For each apherisis over a 12 months period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of reticulocyte (g/L),</measure>
    <time_frame>For each apherisis over a 12 months period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of reticulocyte</measure>
    <time_frame>For each apherisis over a 12 months period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lactate dehydrogenase (UI/L)</measure>
    <time_frame>For each apherisis over a 12 months period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine (mg/L)</measure>
    <time_frame>For each apherisis over a 12 months period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alanine aminotransferase (UI/L)</measure>
    <time_frame>For each apherisis over a 12 months period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspartate aminotransferase (UI/L)</measure>
    <time_frame>For each apherisis over a 12 months period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bilirubin T (mg/dL)</measure>
    <time_frame>For each apherisis over a 12 months period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of alloimmunisation events evaluated with irregular red cell antibodies measure</measure>
    <time_frame>For each apherisis over a 12 months period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaire (SF-36)</measure>
    <time_frame>At baseline and in 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician satisfaction survey for each participant</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>Algorithm (arm A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Frequency and volume for apherisis proposed by algorithm and validated by the physician</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care (arm C)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Frequency and volume for apherisis only decided by the physician (usual care)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Algodrep</intervention_name>
    <description>Algorithm computing the volume of blood to be transfused and the interval between apheresis which are necessary to maintain an individual objective of HbS percentage.</description>
    <arm_group_label>Algorithm (arm A)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or older

          -  Have sickle cell disease, defined as those individuals with HbSS or HbSβ0Thal

          -  Included in a Blood Exchange Transfusion program (apherisis)

          -  Benefiting from social insurance

          -  Accepting to participate in the study and having signed the informed consent

        Exclusion Criteria:

          -  Have sickle cell disease defined with S-β+thal

          -  Receiving EPO treatment

          -  Pregnant or breast-feeding women

          -  Lack of effective contraception in women in childbearing age

          -  Patient under guardianship
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pablo BARTOLUCCI</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henri Mondor Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pablo BARTOLUCCI</last_name>
    <phone>+33 1 49 81 24 40</phone>
    <email>pablo.bartolucci@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elena FOIS</last_name>
    <phone>+33 1 49 81 24 40</phone>
    <email>elena.fois@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>EFS Rhône-Alpes-Auvergne</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <state>Auvergne Rhône-Alpes</state>
        <zip>42277</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Christine AUBREGE-BOUVIER</last_name>
      <phone>+33 4 77 92 85 66</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre de Santé EFS</name>
      <address>
        <city>Besançon</city>
        <state>Bourgogne Franche-Comté</state>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Antoine CARPI</last_name>
      <phone>+33 3 81 61 56 15</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre de Santé EFS</name>
      <address>
        <city>Rennes</city>
        <state>Bretagne</state>
        <zip>35016</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Cathy DUGOR</last_name>
      <phone>+33 2 23 22 53 95</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre de Santé EFS</name>
      <address>
        <city>Tours</city>
        <state>Centre-Val De Loire</state>
        <zip>37206</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Béatrice HERAULT</last_name>
      <phone>+33 2 47 36 01 14</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Kremlin Bicêtre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <state>Ile De France</state>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Christelle CHANTALAT</last_name>
      <phone>+33 1 45 21 71 10</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <state>Ile-de-France</state>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Dehbia MENOUCHE</last_name>
      <phone>+33 1 49 81 42 49</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre de Santé EFS</name>
      <address>
        <city>Bordeaux</city>
        <state>Nouvelle-Aquitaine</state>
        <zip>33035</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Florian THEVENOT</last_name>
      <phone>+33 5 56 90 82 03</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Martinique</name>
      <address>
        <city>Le Lamentin</city>
        <zip>97232</zip>
        <country>Martinique</country>
      </address>
    </facility>
    <contact>
      <last_name>Gylna LOKO</last_name>
      <phone>+33 5 96 48 81 89</phone>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>Martinique</country>
  </location_countries>
  <reference>
    <citation>Quinn CT, Ahmad N. Clinical correlates of steady-state oxyhaemoglobin desaturation in children who have sickle cell disease. Br J Haematol. 2005 Oct;131(1):129-34.</citation>
    <PMID>16173973</PMID>
  </reference>
  <reference>
    <citation>Quinn CT, Sargent JW. Daytime steady-state haemoglobin desaturation is a risk factor for overt stroke in children with sickle cell anaemia. Br J Haematol. 2008 Feb;140(3):336-9. Epub 2007 Nov 27.</citation>
    <PMID>18042265</PMID>
  </reference>
  <reference>
    <citation>Setty BN, Stuart MJ, Dampier C, Brodecki D, Allen JL. Hypoxaemia in sickle cell disease: biomarker modulation and relevance to pathophysiology. Lancet. 2003 Nov 1;362(9394):1450-5.</citation>
    <PMID>14602439</PMID>
  </reference>
  <reference>
    <citation>Nahavandi M, Nichols JP, Hassan M, Gandjbakhche A, Kato GJ. Near-infrared spectra absorbance of blood from sickle cell patients and normal individuals. Hematology. 2009 Feb;14(1):46-8. doi: 10.1179/102453309X385133.</citation>
    <PMID>19154664</PMID>
  </reference>
  <reference>
    <citation>Nahavandi M, Tavakkoli F, Hasan SP, Wyche MQ, Castro O. Cerebral oximetry in patients with sickle cell disease. Eur J Clin Invest. 2004 Feb;34(2):143-8.</citation>
    <PMID>14764078</PMID>
  </reference>
  <reference>
    <citation>Waltz X, Pichon A, Lemonne N, Mougenel D, Lalanne-Mistrih ML, Lamarre Y, Tarer V, Tressières B, Etienne-Julan M, Hardy-Dessources MD, Hue O, Connes P. Normal muscle oxygen consumption and fatigability in sickle cell patients despite reduced microvascular oxygenation and hemorheological abnormalities. PLoS One. 2012;7(12):e52471. doi: 10.1371/journal.pone.0052471. Epub 2012 Dec 20.</citation>
    <PMID>23285055</PMID>
  </reference>
  <reference>
    <citation>Waltz X, Pichon A, Mougenel D, Lemonne N, Lalanne-Mistrih ML, Sinnapah S, Tarer V, Tressières B, Lamarre Y, Etienne-Julan M, Hue O, Hardy-Dessources MD, Connes P. Hemorheological alterations, decreased cerebral microvascular oxygenation and cerebral vasomotion compensation in sickle cell patients. Am J Hematol. 2012 Dec;87(12):1070-3. doi: 10.1002/ajh.23318. Epub 2012 Aug 22.</citation>
    <PMID>22911571</PMID>
  </reference>
  <reference>
    <citation>Belcher JD, Chen C, Nguyen J, Milbauer L, Abdulla F, Alayash AI, Smith A, Nath KA, Hebbel RP, Vercellotti GM. Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease. Blood. 2014 Jan 16;123(3):377-90. doi: 10.1182/blood-2013-04-495887. Epub 2013 Nov 25.</citation>
    <PMID>24277079</PMID>
  </reference>
  <reference>
    <citation>Eltzschig HK, Carmeliet P. Hypoxia and inflammation. N Engl J Med. 2011 Feb 17;364(7):656-65. doi: 10.1056/NEJMra0910283. Review.</citation>
    <PMID>21323543</PMID>
  </reference>
  <reference>
    <citation>Eltzschig HK, Eckle T. Ischemia and reperfusion--from mechanism to translation. Nat Med. 2011 Nov 7;17(11):1391-401. doi: 10.1038/nm.2507. Review.</citation>
    <PMID>22064429</PMID>
  </reference>
  <reference>
    <citation>Lionnet F, Arlet JB, Bartolucci P, Habibi A, Ribeil JA, Stankovic K; groupe de recommandations et d'étude de la drépanocytose de l'adulte (GREDA). [Guidelines for management of adult sickle cell disease]. Rev Med Interne. 2009 Sep;30 Suppl 3:S162-223. doi: 10.1016/j.revmed.2009.07.001. Epub 2009 Aug 26. French.</citation>
    <PMID>19713011</PMID>
  </reference>
  <reference>
    <citation>Adams RJ, McKie VC, Hsu L, Files B, Vichinsky E, Pegelow C, Abboud M, Gallagher D, Kutlar A, Nichols FT, Bonds DR, Brambilla D. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med. 1998 Jul 2;339(1):5-11.</citation>
    <PMID>9647873</PMID>
  </reference>
  <reference>
    <citation>Adams RJ, Brambilla D; Optimizing Primary Stroke Prevention in Sickle Cell Anemia (STOP 2) Trial Investigators. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med. 2005 Dec 29;353(26):2769-78.</citation>
    <PMID>16382063</PMID>
  </reference>
  <reference>
    <citation>Abboud MR, Yim E, Musallam KM, Adams RJ; STOP II Study Investigators. Discontinuing prophylactic transfusions increases the risk of silent brain infarction in children with sickle cell disease: data from STOP II. Blood. 2011 Jul 28;118(4):894-8. doi: 10.1182/blood-2010-12-326298. Epub 2011 Jun 1.</citation>
    <PMID>21633086</PMID>
  </reference>
  <reference>
    <citation>Gueguen A, Mahevas M, Nzouakou R, Hosseini H, Habibi A, Bachir D, Brugière P, Lionnet F, Ribei JA, Godeau B, Girot R, Ibrahima V, Calvet D, Galactéros F, Bartolucci P. Sickle-cell disease stroke throughout life: a retrospective study in an adult referral center. Am J Hematol. 2014 Mar;89(3):267-72.</citation>
    <PMID>24779035</PMID>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 26, 2019</study_first_submitted>
  <study_first_submitted_qc>August 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 3, 2019</study_first_posted>
  <last_update_submitted>August 30, 2019</last_update_submitted>
  <last_update_submitted_qc>August 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Algorithm</keyword>
  <keyword>Apherisis</keyword>
  <keyword>Sickle cell patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

